HealthdirectFree Australian health advice you can count on.

( ARTG ) Acromegaly: For the symptomatic control and reduction of growth hormone and IGF-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment, but who are adequately controlled on subcutaneous treatment with Sandostatin.‍‍‍‍‍‍​​​‍​​​​​​ Sandostatin LAR is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,Gastro-entero-pancreatic tumours: For the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: - Carcinoid tumours with features of the carcinoid syndrome; - Vasoactive intestinal peptide secreting tumours (VIPomas) in patients who are adequately controlled on subcutaneous treatment with Sandostatin. Sandostatin LAR is not curative in these patients.,Advanced neuroendocrine tumours of the midgut: Treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.